Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders
Authors: Pornpen Srisawasdi
Natchaya Vanwong
Yaowaluck Hongkaew
Apichaya Puangpetch
Somlak Vanavanan
Boontarika Intachak
Nattawat Ngamsamut
Penkhae Limsila
Chonlaphat Sukasem
Martin H. Kroll
Mahidol University
Faculty of Medicine, Thammasat University
Thailand Ministry of Public Health
Quest Diagnostics
Keywords: Biochemistry, Genetics and Molecular Biology
Issue Date: 1-Aug-2017
Citation: Clinical Biochemistry. Vol.50, No.12 (2017), 678-685
Abstract: © 2017 The Canadian Society of Clinical Chemists Objective To evaluate the influence of dose and duration of risperidone treatment on cardiovascular and diabetes risk biomarkers in children and adolescents with autistic spectrum disorders (ASDs). Design and methods In this cross-sectional analysis, a total of 168 ASDs patients (89% male) treated with a risperidone-based regimen for ≥ 12 months were included. Blood samples were analyzed for glucose and lipid metabolic markers, adiponectin, leptin, prolactin, cortisol and high sensitive C-reactive protein. Results The mean concentrations of glucose, insulin, prolactin and leptin and HOMA-IR significantly rose with risperidone dosage (all P < 0.025), but those of adiponectin and cortisol did not. Using regression analysis, insulin, leptin, prolactin and glucose concentrations and HOMA-IR show significant association with dosage. None of the markers except adiponectin showed dependence on duration of treatment. However, insulin and leptin concentrations and HOMA-IR clearly increased with increasing both dosage and duration. Dosage and duration of treatment had minimal effect on standard lipid profile and lipoprotein subclasses. Conclusions Risperidone treatment disturbed glucose homeostasis and endocrine regulation (particularly leptin) in children and adolescents with ASDs, in a dose- and duration-dependent manner, being suggestive of leptin and insulin resistance mechanisms. Metabolic adverse effects, especially development of type 2 diabetes mellitus should be closely monitored, particularly in individuals receiving high doses and/or long-term risperidone treatment.
ISSN: 18732933
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.